Technology Innovation Institute Introduces World’s Most Powerful Open LLM: Falcon 180B
The Technology Innovation Institute (TII) in the United Arab Emirates (UAE) is pushing the boundaries of generative AI once again with the launch of Falcon 180B, an advanced iteration of its flagship large language model (LLM). This groundbreaking release strengthens the UAE's dominance in AI, offering Falcon 180B as an open access model for research and commercial purposes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906583274/en/
Falcon 180B Benchmarks (Photo: AETOSWire)
Following the remarkable success of Falcon 40B, an open source AI model that swiftly ascended to the top of the Hugging Face Leaderboard for LLMs in May 2023, TII, the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) continues to lead the charge in generative AI. Falcon 40B marked one of the first instances of open source models for both researchers and commercial users, and it was considered a pioneering leap in the field.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council, emphasized the positive impact of Falcon on the AI landscape and said: “We envision a future where the transformative power of AI is within everyone's reach. We are committed to democratizing access to advanced AI, as our privacy and the potential impact of AI on humanity should not be controlled by a select few. While we may not have all the answers, our resolve remains unwavering: to collaborate and contribute to the open source community, ensuring that the benefits of AI are shared by all.”
With a staggering 180 billion parameters and trained on 3.5 trillion tokens, Falcon 180B soars to the top of the Hugging Face Leaderboard for pretrained LLMs. It outperforms notable competitors like Meta’s LLaMA 2 in various benchmarks, including reasoning, coding, proficiency, and knowledge tests.
Among the best closed source LLMs, Falcon 180B ranks just behind OpenAI's latest GPT 4 and is on par with the performance of Google's PaLM 2 Large, the model powering Bard – despite being half the size of the model. The licensing framework for the model is established on ‘Falcon 180B TII License’, which is based upon Apache 2.0.
Dr. Ebtesam Almazrouei, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: "The launch of Falcon 180B exemplifies our dedication to advancing the frontiers of AI, and we are thrilled to share its limitless potential with the world. Falcon 180B heralds a new era of generative AI, where the potential of scientific advancement is made available through open access to fuel the innovations of tomorrow. As we delve into frontiers of science and technology, our vision extends far beyond innovation; it's about nurturing a profound connection to address global challenges through collaborative breakthroughs.”
With over 12 million developers adopting and deploying the first release of Falcon, this significant upgrade is poised to become the premier model for various domains, from chatbots to code generation, and beyond.
Falcon 180B is compatible with the following major languages: English, German, Spanish, and French, with limited capabilities in Italian, Portuguese, Polish, Dutch, Romanian, Czech, and Swedish.
For more information, please visit FalconLLM.tii.ae
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906583274/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom